NASDAQ:COYA
Coya Therapeutics, Inc.
Coya Therapeutics, Inc.'s revenue grew 123.6% in fiscal 2025 to $7.9M while operating margin rose to −283.9%. The diluted share count rose 9.8%.Summary generated from Coya Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 16, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$7.9M
Revenue growth+123.6%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−283.9%
Net margin−267.1%
ROICn/a
Return on equity−51.4%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+9.8%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | 0 | 6 | 4 | 8 |
| Operating income | −5 | −10 | −8 | −17 | −23 |
| Net income | −5 | −12 | −8 | −15 | −21 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 8-KOther events
Oct 5, 2026 - 8-KOther events
Sep 15, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 8-K/AAmended director or officer change
Aug 7, 2026 - 8-KResults of a shareholder vote
Jun 25, 2026 - DEF 14AProxy statement
May 13, 2026 - 8-KEntry into a material agreement
May 12, 2026